Early-Stage drug trial for rare hormone disorder in kids ends early
NCT ID NCT02574910
First seen Nov 04, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tested a drug called abiraterone acetate in 4 children with congenital adrenal hyperplasia (CAH), a condition that causes hormone imbalances and early growth problems. The goal was to see if it could lower the dose of hydrocortisone needed to control the disease. The study was stopped early due to low enrollment, so no clear conclusions could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Medical Center
Dallas, Texas, 75235, United States
-
National Institutes of Health
Bethesda, Maryland, 20892-1932, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.